Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.77 |
| ▸ | JAK3 | P52333 | 6/20 | 0.77 |
| ▸ | JAK1 | P23458 | 4/20 | 0.77 |
| ▸ | EGFR | P00533 | 11/20 | 0.59 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.56 |
| ▸ | ITK | Q08881 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | BLK | P51451 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19550929 | 0.87 | JAK2 (1.00) | JAK2JAK3JAK1EGFRMAP2K7 | |
| SCHEMBL13860290 | 0.87 | EGFR (0.77) | JAK2JAK3JAK1EGFRMAP2K7 | |
| SCHEMBL27586636 | 0.87 | EGFR (0.77) | JAK2JAK3JAK1EGFRMAP2K7 | |
| SCHEMBL4827998 | 0.87 | EGFR (0.77) | JAK2JAK3JAK1EGFRMAP2K7 | |
| SCHEMBL19724243 | 0.86 | JAK2 (0.76) | JAK2JAK3JAK1EGFRMAP2K7 | |
| SCHEMBL20875026 | 0.86 | JAK2 (0.76) | JAK2JAK3JAK1EGFRITK | |
| SCHEMBL19724281 | 0.86 | JAK2 (0.75) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL19871054 | 0.86 | JAK2 (0.75) | JAK2JAK3JAK1EGFRMAP2K7 | |
| SCHEMBL19724283 | 0.86 | JAK2 (0.75) | JAK2JAK3JAK1EGFRBTK | |
| SCHEMBL14630545 | 0.85 | JAK2 (0.68) | JAK2JAK3JAK1EGFRMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196397-B2 | Process for the preparation of ibrutinib | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2019-02-05 | — | — | US | disclosed |
| US-20170320879-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| EP-3221320-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | Sun Pharmaceutical Industries Ltd (IN) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079693-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320879-A1 | A PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, IGLV6-57 | JAK2 12/4885JAK3 25/4885JAK1 15/4885 |
| US-10196397-B2 | Process for the preparation of ibrutinib | BTK, IGLV6-57, SYK | JAK2 11/4885JAK3 26/4885JAK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.